QLGN
Income statement / Annual
Last year (2023), Qualigen Therapeutics, Inc.'s total revenue was $5.20 M,
an increase of 4.44% from the previous year.
In 2023, Qualigen Therapeutics, Inc.'s net income was -$13.42 M.
See Qualigen Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
03/31/2020 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$5.20 M |
$4.98 M |
$5.65 M |
$4.31 M |
$5.56 M |
$5.80 M |
$9.78 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$5.21 M
|
$4.30 M
|
$4.33 M
|
$7.19 M
|
$3.98 M
|
$5.42 M
|
$7.90 M
|
$18.45 M
|
$8.91 M
|
$3.48 K
|
| Gross Profit |
-$4.50 K
|
$680.80 K
|
$1.32 M
|
-$2.88 M
|
$1.58 M
|
$378.39 K
|
$1.87 M
|
-$18.45 M
|
-$8.91 M
|
-$3.48 K
|
| Gross Profit Ratio |
-0
|
0.14
|
0.23
|
-0.67
|
0.28
|
0.07
|
0.19
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.21 M
|
$6.84 M
|
$11.72 M
|
$3.55 M
|
$1.21 M
|
$1.32 M
|
$2.87 M
|
$13.29 M
|
$2.26 M
|
$113.93 K
|
| General & Administrative Expenses |
$6.10 M
|
$10.84 M
|
$11.72 M
|
$8.02 M
|
$1.51 M
|
$1.05 M
|
$4.78 M
|
$4.88 M
|
$6.40 M
|
$0.00
|
| Selling & Marketing Expenses |
-$4.50 K
|
$950.42 K
|
$542.59 K
|
$400.17 K
|
$367.95 K
|
$380.34 K
|
$618.46 K
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.09 M
|
$11.79 M
|
$12.27 M
|
$8.42 M
|
$1.88 M
|
$1.43 M
|
$4.78 M
|
$4.88 M
|
$6.40 M
|
$2.16 M
|
| Other Expenses |
-$5.21 M
|
$1.13 K
|
$5.45 K
|
$0.00
|
$2.79 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$6.10 M
|
$18.62 M
|
$23.98 M
|
$17.40 M
|
$3.08 M
|
$1.42 M
|
$7.65 M
|
$18.17 M
|
$8.66 M
|
$2.28 M
|
| Cost And Expenses |
$11.30 M
|
$22.93 M
|
$28.32 M
|
$24.59 M
|
$7.06 M
|
$6.85 M
|
$15.55 M
|
$36.62 M
|
$17.57 M
|
$2.28 M
|
| Interest Income |
$0.00
|
$26.65 K
|
$42.69 K
|
$138.80 K
|
$123.05 B
|
$152.04 K
|
$40.23 K
|
$60.88 K
|
$40.88 K
|
$525.00
|
| Interest Expense |
$1.52 M
|
$26.65 K
|
$0.00
|
$0.00
|
$283.10 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$213.52 K
|
| Depreciation & Amortization |
$4.50 K
|
$12.17 K
|
$322.06 K
|
$138.65 K
|
$111.38 K
|
$5.70 K
|
$5.70 K
|
$5.21 K
|
$1.94 K
|
$3.48 K
|
| EBITDA |
-$11.30 M |
-$13.84 M |
-$22.66 M |
-$11.16 M |
-$10.02 M |
-$717.86 K |
-$7.86 M |
-$18.38 M |
-$8.79 M |
-$2.26 M |
| EBITDA Ratio |
-2.17
|
-2.78
|
-4.01
|
-2.59
|
-1.8
|
-0.12
|
-0.8
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.17
|
-3.6
|
-4.01
|
-2.62
|
-0.27
|
-0.18
|
-1.59
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.17 M
|
$872.81 K
|
$4.77 M
|
-$7.74 M
|
$711.17 K
|
-$140.55 K
|
$38.60 K
|
$18.24 M
|
$8.79 M
|
-$191.85 K
|
| Income Before Tax |
-$12.48 M
|
-$21.30 M
|
-$17.89 M
|
-$20.42 M
|
-$1.78 M
|
-$1.20 M
|
-$7.86 M
|
-$18.38 M
|
-$9.18 M
|
-$2.47 M
|
| Income Before Tax Ratio |
-2.4
|
-4.27
|
-3.16
|
-4.74
|
-0.32
|
-0.21
|
-0.8
|
0
|
0
|
0
|
| Income Tax Expense |
-$4.79 K
|
-$265.07 K
|
$5.43 K
|
$619.00
|
$4.00 K
|
$4.62 K
|
$5.09 K
|
-$5.21 K
|
-$1.94 K
|
$0.00
|
| Net Income |
-$13.42 M
|
-$21.03 M
|
-$17.90 M
|
-$20.42 M
|
-$1.79 M
|
-$1.20 M
|
-$7.86 M
|
-$18.38 M
|
-$9.18 M
|
-$2.47 M
|
| Net Income Ratio |
-2.58
|
-4.22
|
-3.17
|
-4.74
|
-0.32
|
-0.21
|
-0.8
|
0
|
0
|
0
|
| EPS |
-2.46 |
-5.48 |
-6.1 |
-28.21 |
-2.85 |
-2.26 |
-14.04 |
-20.44 |
-31.15 |
-794 |
| EPS Diluted |
-2.46 |
-5.48 |
-6.1 |
-28.21 |
-2.85 |
-2.26 |
-14.04 |
-20.44 |
-31.15 |
-794 |
| Weighted Average Shares Out |
$5.07 M
|
$3.84 M
|
$2.93 M
|
$723.72 K
|
$627.00 K
|
$530.47 K
|
$560.22 K
|
$899.33 K
|
$294.68 K
|
$3.12 K
|
| Weighted Average Shares Out Diluted |
$5.07 M
|
$3.84 M
|
$2.93 M
|
$723.72 K
|
$627.00 K
|
$530.47 K
|
$560.22 K
|
$899.33 K
|
$294.68 K
|
$3.12 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
